ACUTE MYELOID LEUKEMIA REFRACTORY
Clinical trials for ACUTE MYELOID LEUKEMIA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA REFRACTORY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat leukemia
Disease control TerminatedThis trial tests a new therapy called CART123 for adults with acute myeloid leukemia (AML) that has not responded to standard treatments or has returned after treatment. The therapy uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cell…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Cord blood immune cells tested against tough leukemia
Disease control TerminatedThis early-phase trial tested a new treatment for adults with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment involved giving patients natural killer cells grown from donated umbilical cord blood, along with a drug called IL-2 to help…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cell therapy targets tough childhood leukemia
Disease control TerminatedThis early-phase study tested a new treatment for children and young adults with acute myeloid leukemia (AML) that returned or didn't respond to standard therapy. The treatment involved taking patients' own immune cells, engineering them to recognize and attack leukemia cells (CA…
Matched conditions: ACUTE MYELOID LEUKEMIA REFRACTORY
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC